2024-03-29T13:40:35Z
https://soar-ir.repo.nii.ac.jp/oai
oai:soar-ir.repo.nii.ac.jp:00004341
2023-02-24T00:55:41Z
461:463:464:549
リンパ節転移陰性乳癌組織におけるthymidine phosphorylase発現症例の検討
Clinicopathological Significance of Thymidine Phosphorylase Expressed in Node-Negative Breast Cancer Tumors
本原, 昭子
麻沼, 和彦
藤森, 実
土屋, 眞一
浜, 善久
丸山, 正幸
草間, 律
天野, 純
thymidine phosphorylase
node-negative
breast cancer
medroxyprogesterone
doxifluridine
チミジンホスホリラーゼ
リンパ節陰性
乳癌
メドロキシプロゲステロン
ドキシフルリジン
The expression of thymidine phosphorylase (dThd Pase) in node-negative human invasive ductal carcinoma tissues was investigated by the immunocytochemical method using anti-thymidine phosphorylase monoclonal antibody.Subjects were 5 recurrent and 30 non-recurrent patients who underwent surgery at the Department of Surgery at Shinshu University Hospital between 1993 and 1996.The median follow-up period was 62.5 months.Positive dThd Pase staining was observed in the five recurrent and four non-recurrent cases. Tumor recurrence was significantly more developed in patients with dThd Pase positive staining than in those with negative staining (p<0.01).Among the nine dThd Pase positive cases,four patients who were administered doxifluridine (5’-DFUR) or medroxyprogesterone (MPA) did not manifest recurrence. Among the recurrent patients, two were cured by oral administration of 5’-DFUR or MPA. It is suggested that the expression of thymidine phosphorylase in human breast cancer tissues may be a risk factor for tumor recurrence. The prognosis of node-negative and dThd Pase positive breast cancer patients might be improved by hormonal therapy or oral administration of 5’-DFUR.
Article
信州医学雑誌 49(2): 79-83(2001)
journal article
信州医学会
2001-04
application/pdf
信州医学雑誌
2
49
79
83
0037-3826
AN00120815
https://soar-ir.repo.nii.ac.jp/record/4341/files/Shinshu_Med49-2-03.pdf
jpn